首页> 外国专利> PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ASTHMA CONTAINING MAACKIAIN AS AN ACTIVE INGREDIENT

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ASTHMA CONTAINING MAACKIAIN AS AN ACTIVE INGREDIENT

机译：预防或治疗含有麦凯恩作为活性成分的哮喘的药物组合物

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to a pharmaceutical composition for preventing or treating asthma containing maackiain as an active ingredient. The maackiain of the present invention can be used to advantage as a composition for preventing, treating and alleviating asthma because it has an outstanding effect in suppressing the production of ovalbumin and in particular IgE in serum and bronchoalveolar lavage fluid and in suppressing the expression of Th2 cytokines in the lungs, in addition to suppressing the volume of active oxygen created in the respiratory tract and suppressing the infiltration of inflammatory cells into the bronchi and relieving respiratory-tract hypersensitivity which constitute problems that cause asthma in in-vivo studies.

机译：预防或治疗哮喘的药物组合物技术领域本发明涉及一种预防或治疗哮喘的药物组合物，该药物组合物包含毛花果苷作为有效成分。由于本发明的maackiain在抑制血清和支气管肺泡灌洗液中卵清蛋白，特别是IgE的产生以及抑制Th2的表达方面具有突出的作用，因此可以有利地用作预防，治疗和减轻哮喘的组合物。肺中的细胞因子，除了抑制呼吸道中产生的活性氧的量并抑制炎症细胞向支气管的浸润并缓解呼吸道超敏性外，这些都是导致体内哮喘的问题学习。 展开▼

著录项

公开/公告号WO2012128496A3

专利类型

公开/公告日2012-11-15

原文格式PDF

申请/专利权人 KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;LEE HYEONG KYU;AHN KYUNG SEOP;JANG HA YOUNG;KIM SEMI;OH SEI RYANG;KIM DOO-YOUNG;KIM JUNG HEE;
展开▼

申请/专利号WO2012KR01810

发明设计人 LEE HYEONG KYU;AHN KYUNG SEOP;JANG HA YOUNG;KIM SEMI;OH SEI RYANG;KIM DOO-YOUNG;KIM JUNG HEE;
展开▼

申请日2012-03-13

分类号A61K31/36;A61K36/48;A61P11/06;

国家 WO

入库时间 2022-08-21 16:36:47

相似文献

专利

外文文献

中文文献

1. 从东北婆婆纳中分离的含有大量活性成分的纯化提取物、其制备以及包含该提取物作为活性成分用于预防或治疗炎症、过敏和哮喘的组合物 [P] . 中国专利： CN104822386B . 2016.08.31

2. 从东北婆婆纳中分离的含有大量活性成分的纯化提取物、其制备以及包含该提取物作为活性成分用于预防或治疗炎症、过敏和哮喘的组合物 [P] . 中国专利： CN104822386A . 2015-08-05

3. PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ASTHMA CONTAINING MAACKIAIN AS AN ACTIVE INGREDIENT [P] . 世界知识产权组织专利： WO2012128496A2 . 2012-09-27

机译：预防或治疗含有麦凯恩作为活性成分的哮喘的药物组合物

4. 4-SUBSTITUTED OXAZOLO-QUINOLINONE DERIVATIVE, COMPOUND WHICH IS PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES SUCH AS ASTHMA, ATOPY, ETC. INCLUDING SAME AS ACTIVE INGREDIENT [P] . 韩国专利： KR20200004752A . 2020-01-14

机译： 4取代的恶唑基-喹啉酮衍生物，其药学上可接受的盐，以及用于预防或治疗诸如哮喘，足癣等的过敏性疾病的药物成分。包括相同的活性成分

5. PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ASTHMA WHICH CONTAINS 4-HYDROXY-3-METHOXY PHENYL BUTENONE DERIVATIVE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT [P] . 韩国专利： KR20130084512A . 2013-07-25

机译：预防或治疗哮喘的药物组合物，其中含有4-羟基-3-甲氧基苯丁酸丁烯酮衍生物或作为活性成分的药学上可接受的盐

1. Simultaneous and Trace Level Quantification of Five Potential Genotoxic Impurities in Ranolazine Active Pharmaceutical Ingredient Using LC-MS/MS [J] . Kartheek Srinivas Chidella, Vijaya Bharathi Dasari, Jayashree Anireddy 美国分析化学（英文） . 2021,第001期

2. Development of a rapid GC-FID method to simultaneously determine triethylamine,diisopropylamine,and 1,1,3,3-tetramethylguanidine residues in an active pharmaceutical ingredient [J] . Minshan Shou, Haixiao Qiu 药物分析学报（英文） . 2021,第002期

3. Multiple Emulsions Able to Be Used for Oral Administration of Active Pharmaceutical Ingredients: Physico-Chemical Parameters Study of Different Phases [J] . Louis Augustin Diaga Diouf, Alphonse Rodrigue Djiboune, Mamadou Soumboundou, 现代物理（英文） . 2020,第010期

4. Treatability Study of Wasterwater Generated at Manufacturing Unit of Pharmaceutical Intermediates and Active Pharmaceutical Ingredients [J] . Arti D. Galgale, Nirav G. Shah, Devki R. Parikh Indian Journal of Environmental Protection . 2013,第3期

5. Treating Active Pharmaceutical Ingredients in Manufacturing Wastewater [J] . Jonathan Rhone Water Technology . 2020,第1期

6. Single-run ultra-high performance liquid chromatography for quantitative determination of ultra-traces of ten popular active pharmaceutical ingredients by quadrupole time-of-flight mass spectrometry after offline preconcentration by solid phase extraction from drinking and river waters as well as treated wastewater [J] . Krakko Daniel, Licul-Kucera Viktoria, Zaray Gyula, Microchemical Journal: Devoted to the Application of Microtechniques in all Branches of Science . 2019,第期

7. Potential of THz-TDS for Crystallinity State Inspection of Active Pharmaceutical Ingredients in SmartFilms® [C] . Jan Ornik, Daniel Knoth, Cornelia M. Keck, International Conference on Infrared, Millimeter, and Terahertz Waves . 2020

8. Effect of Compression Force on Agglomeration of Micronized Active Pharmaceutical Ingredients: Techniques to Prevent API Agglomeration during Compression. [D] . Potharaju, Suresh. 2012

9. Protocol for a four parallel-arm single-blind cluster-randomised trial to assess the effectiveness of three types of dual active ingredient treated nets compared to pyrethroid-only long-lasting insecticidal nets to prevent malaria transmitted by pyrethroid insecticide-resistant vector mosquitoes in Tanzania [O] . Jacklin F. Mosha, Manisha A. Kulkarni, Louisa A. Messenger, 2021

10. Compositional effect of complex biorelevant media on the crystallization kinetics of an active pharmaceutical ingredient [O] . Jennifer Lu, James D. Ormes, Michael Lowinger, 2017

1. Simultaneous Determination of N-Acetyl Cysteine and Taurine by HPTLC Method in Active Pharmaceutical Ingredient and Pharmaceutical Dosage Form [J] . A. R. Magesh ,Magharla Dasaratha Dhanaraju . 美国分析化学（英文） . 2017,第11期

2. Analysis of the Current Situation of Active Pharmaceutical Ingredient (API) Export in China [J] . Kong Deqiang1 ,Dong Li1 . 亚洲社会药学 . 2019,第003期

3. 《使病变组织脱水萎缩消除的药物组合物》注射术治疗痔疮及肛门肿瘤息肉130例报告 [C] . 谭国梁 ,谭晓雯 ,谭晓晴 . 2010中国结直肠肛门外科学术年会暨第十四届中日大肠肛门病学术会/第二十届上海长海国际肛肠外科周 . 2010

4. 天灸治疗支气管哮喘：优化药物处方和穴位组合的随机对照临床试验 [A] . 智勇 . 2015